Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Famotidine

FDA-approved product (tablet, oral), marketed as Famotidine, Famotidine Preservative Free, Famotidine Preservative Free (Pharmacy Bulk) and 7 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Famotidine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chest pain
  • Duodenal ulcer
  • Dyspepsia
  • Esophagitis
  • Gastric ulcer
  • Gastroesophageal reflux disease
  • Osteoarthritis
  • Peptic ulcer
  • Rheumatoid arthritis
  • Ulcer disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
H2-receptor antagonists
FDA pharmacologic class
Histamine-2 Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Famotidine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Famotidine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fed Condition

    NCT01079052 · start 2007-11

    Registered record
    Registry ID
    NCT01079052
    Conditions
    Healthy
    Interventions
    Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-11
    Completion
    2007-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionFamotidine
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment

    NCT00450216 · start 2007-03

    Registered record
    Registry ID
    NCT00450216
    Conditions
    Ulcer
    Interventions
    Ibuprofen/famotidine; Ibuprofen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-03
    Completion
    2008-10
    Enrolment
    906

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcer
    InterventionIbuprofen/famotidine; Ibuprofen
    PhasePhase 3
    Registry statusCompleted

  • Ulcer Prevention Study in Post Gastric Bypass Patients

    NCT00557349 · start 2006-11

    Registered record
    Registry ID
    NCT00557349
    Conditions
    Marginal Ulcers
    Interventions
    Omeprazole; Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-11
    Completion
    2008-03
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMarginal Ulcers
    InterventionOmeprazole; Famotidine
    PhasePhase 4
    Registry statusCompleted

  • A Study to Assess the Bioequivalence of Famotidine Chewable Tablets and Film-Coated Tablets (0208-144)

    NCT00945750 · start 2006-08

    Registered record
    Registry ID
    NCT00945750
    Conditions
    Heartburn
    Interventions
    Famotidine FCT; Famotidine CT
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-08
    Completion
    2006-09
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeartburn
    InterventionFamotidine FCT; Famotidine CT
    PhasePhase 1
    Registry statusCompleted

  • Bioequivalence Study Between Two Oral Formulations of Famotidine Tablets Under Fasting Conditions

    NCT00802828 · start 2004-06

    Registered record
    Registry ID
    NCT00802828
    Conditions
    Bioavailability
    Interventions
    Famotidine Tablets, 40 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-06
    Completion
    Not recorded
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioavailability
    InterventionFamotidine Tablets, 40 mg
    PhasePhase 1
    Registry statusCompleted